{
    "organizations": [],
    "uuid": "b8256df15268436b34bf5e864a427ace1ccaabf8",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-us-fda-approves-new-hiv-treatment/brief-u-s-fda-approves-new-hiv-treatment-for-patients-who-have-limited-treatment-options-idUSFWN1QO0PN",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Approves New HIV Treatment For Patients Who Have Limited Treatment Options",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - U.S. Food and Drug Administration:\n* U.S. FDA SAYS APPROVED ANTIRETROVIRAL MEDICATION TROGARZO (IBALIZUMAB-UIYK) FOR ADULT HIV PATIENTS WHO HAVE TRIED MULTIPLE HIV MEDICATIONS BEFORE\n* U.S. FDA SAYS GRANTED APPROVAL OF TROGARZO TO TAIMED BIOLOGICS USA CORP Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T02:23:00.000+02:00",
    "crawled": "2018-03-07T19:25:05.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "food",
        "drug",
        "administration",
        "fda",
        "say",
        "approved",
        "antiretroviral",
        "medication",
        "trogarzo",
        "adult",
        "hiv",
        "patient",
        "tried",
        "multiple",
        "hiv",
        "medication",
        "fda",
        "say",
        "granted",
        "approval",
        "trogarzo",
        "taimed",
        "biologics",
        "usa",
        "corp",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}